摘要
目的探讨急性胰腺炎患者治疗中生长抑素的临床应用效果。方法选取我院2013年1月～2015年12月收治的急性胰腺炎患者，共81例，经患者知情同意后双盲分组，给予对照组41例常规治疗，观察组40例采用常规治疗的同时加用生长抑素治疗；对两组临床疗效与并发症情况进行比较。结果观察组血淀粉酶恢复、白细胞计数恢复、症状缓解时间、痊愈时间，均明显短于对照组（P均〈0．05）；并发症方面，观察组5例（12．5％）明显少于对照组11例（26．83％），差异有统计学意义（P〈0．05）；观察组临床总有效35例（87．50％）明显高于对照组28例（62．29％），临床总疗效组间差异有统计学意义（P〈0．05）。结论生长抑素可抑制病情发展，缩短病程，降低并发症发生，值得临床推广。
Objective To investigate the clinical effect of somatostatin patients with acute pancreatitis. Methods 81 cases of patients with acute pancreatitis admitted in our hospital from January 2013 to December 2015 were selected as the study objects.Double-blind packet was used after informed consent of patients.Patients in control group （41 cases） were given conventional treatment,and patients in observation group （40 cases） were given somatostatin on the basis of conventional therapy.Clinical efficacy and complications of the two groups were compared. Results The serum amylase,white blood cell count recovery,remission time,recovery time of observation group were significantly shorter than those of control group （P 〈 0.05）.There were 5 cases 02.5%） with complications in observation group,which was significantly lower than that in control group with 11 cases （26.83%）,and the difference was significant （P 〈0.05）.Total effective count of observation group was 35 cases （87.50%）,which was significantly higher than that of control group with 28 cases （62.29%）,and total clinical efficacy between the two groups was significant （P 〈 0.05）. Conclusion Somatostatin can inhibit the progression of the disease,can shorten the course,and can reduce complications.It is worthy of promotion.
出处
《中国医药科学》
2016年第15期71-73,共3页
China Medicine And Pharmacy
关键词
急性胰腺炎
生长抑素
临床疗效
并发症
Acute pancreatitis
Somatostatin
Clinical efficacy
Complication
